- Home
- ZION vs TECH Comparison
ZION vs TECH Comparison
Compare ZION & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | TECH |
|---|---|---|
| Founded | 1873 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 11.4B |
| IPO Year | 2012 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ZION | TECH |
|---|---|---|
| Price | N/A | $72.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | | 11 |
| Target Price | N/A | $71.82 |
| AVG Volume (30 Days) | N/A | 2.3M |
| Earning Date | 09-17-2026 | 05-06-2026 |
| Dividend Yield | N/A | 0.62% |
| EPS Growth | N/A | 152.17 |
| EPS | N/A | 1.16 |
| Revenue | N/A | $1,215,039,000.00 |
| Revenue This Year | N/A | $2.49 |
| Revenue Next Year | N/A | $6.40 |
| P/E Ratio | N/A | $62.40 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $43.20 |
| 52 Week High | N/A | $72.62 |
Technical Indicators
Market Signals| Indicator | ZION | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 61.51 |
| Support Level | $67.89 | $72.14 |
| Resistance Level | $72.47 | $72.62 |
| Average True Range (ATR) | 1.28 | 0.16 |
| MACD | 0.09 | -0.13 |
| Stochastic Oscillator | 46.03 | 71.43 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.